jarir atthobari - clinical trial
TRANSCRIPT
![Page 1: Jarir Atthobari - Clinical Trial](https://reader033.vdocuments.mx/reader033/viewer/2022051314/54fa9aa94a7959575b8b48a9/html5/thumbnails/1.jpg)
Clinical trial
Bagian Farmakologi dan ToksikologiFak. Kedokteran, Gadjah Mada University
![Page 2: Jarir Atthobari - Clinical Trial](https://reader033.vdocuments.mx/reader033/viewer/2022051314/54fa9aa94a7959575b8b48a9/html5/thumbnails/2.jpg)
Phase – III Clinical Trial
Randomized Controlled Trial
Ukuran sampel yang besar
Mengevaluasi obat ‘baru’ vs. control (positif/negatif)
Paling mahal dan time consuming
Obat diuji dengan metodologi yang ketat
![Page 3: Jarir Atthobari - Clinical Trial](https://reader033.vdocuments.mx/reader033/viewer/2022051314/54fa9aa94a7959575b8b48a9/html5/thumbnails/3.jpg)
Steps for RCT Design
1. Seleksi subyek penelitian
2. Jenis dan bentuk perlakuan
3. Randomisasi
4. Blinding
5. Pengukuran outcome
6. Analisa data
![Page 4: Jarir Atthobari - Clinical Trial](https://reader033.vdocuments.mx/reader033/viewer/2022051314/54fa9aa94a7959575b8b48a9/html5/thumbnails/4.jpg)
1. Appropriate to the study question2. Generalizable3. Consider the outcome of interest4. Allow adequate recruitment (study
patients you have access to)
Kriteria inklusi
1. Exclude patients with conditions that will compete with the outcomes (e.g. likely early death from cancer)
2. Contradictions to interventions3. Difficult to comply
Kriteria eksklusi
1. Seleksi subyek penelitian
![Page 5: Jarir Atthobari - Clinical Trial](https://reader033.vdocuments.mx/reader033/viewer/2022051314/54fa9aa94a7959575b8b48a9/html5/thumbnails/5.jpg)
• Male and female outpatients• Clinically diagnosed as CAP• Chest-X-ray: pulmonary infiltrate or consolidation• Showing at least three of the following symptom/sign:
– nonproductive cough, – new onset of purulent sputum (productive cough), or– change in the character of their sputum; – sputum culture positive for gram-positive diplococci;– body temperature of 38 7C or more at least twice within a 24 h
period; and/or – elevated leukocyte count (10x10 9 /l).
RCT: azithromycin vs. clarithromycin for adult with mild to moderate CAP
![Page 6: Jarir Atthobari - Clinical Trial](https://reader033.vdocuments.mx/reader033/viewer/2022051314/54fa9aa94a7959575b8b48a9/html5/thumbnails/6.jpg)
Example of exclusion criteria
• Terminal illness• Any condition that could interfere with the attendance
schedule• Patient with the followings:
1. Likely to affect gastrointestinal absorption of antimicrobial activity
2. significant hepatic disease with a serum transaminaselevel more than three times the upper limit of the normal range [serum glutamic oxalacetic transaminase (SGOT) 0.02–0.90 mM/s/; serum glutamic pryruvic transaminase(SGPT) 0.15–0.95 mM/s/l].
3. hypersensitive to azithromycin, clarithromycin, or other macrolide, cyclosporine, theophylline, astemizole, terfenadine, or antacids
![Page 7: Jarir Atthobari - Clinical Trial](https://reader033.vdocuments.mx/reader033/viewer/2022051314/54fa9aa94a7959575b8b48a9/html5/thumbnails/7.jpg)
TreatmentTreatment ControlControl
• Drug formulation • therapeutic class• dosage• drug administration,
frequency• duration of treatment
• standard drug (DOC)• placebo
• non fatal outcome/ disease
Treatment & Control groupTreatment & Control group
2. Jenis dan bentuk perlakuan
![Page 8: Jarir Atthobari - Clinical Trial](https://reader033.vdocuments.mx/reader033/viewer/2022051314/54fa9aa94a7959575b8b48a9/html5/thumbnails/8.jpg)
Sama dalam hal• bentuk• rupa• warna• rasa• bau• konsistensi• cara pemberian
Obat/intervensi
![Page 9: Jarir Atthobari - Clinical Trial](https://reader033.vdocuments.mx/reader033/viewer/2022051314/54fa9aa94a7959575b8b48a9/html5/thumbnails/9.jpg)
RANDOMIZATION
� Objective measures� Equal chance for treatment or control group� Both groups are balanced� To prevent bias
Simple randomization
Randompermuted block
Randompermuted block
within strata
metode
3. Randomize
![Page 10: Jarir Atthobari - Clinical Trial](https://reader033.vdocuments.mx/reader033/viewer/2022051314/54fa9aa94a7959575b8b48a9/html5/thumbnails/10.jpg)
RANDOMIZATION
2 treatment groups: (0-4= A; 5-9=B)
3 treatment groups: (1-3= A; 4-6= B; 7-9 = C)
4 treatment groups (1-2= A; 3-4= B; 5-6= C; 7-9=D)
Simple randomizationSimple randomization
![Page 11: Jarir Atthobari - Clinical Trial](https://reader033.vdocuments.mx/reader033/viewer/2022051314/54fa9aa94a7959575b8b48a9/html5/thumbnails/11.jpg)
128 131 133 142 144 145154 160 162 164 167 181184 188 191 202 203 205216 229 235 237 238 240261 264 272 273 277 278280 281 282 283 289 290291 295 300 312 318 321323 325 327 331 335 338342 349 359 360 366 369372 373 375 384 385 397404 405 414 424 431 436438 446 447 448 458 462469 478 491 498 502 511516 518 520 521 530 535
RANDOM LISTS
![Page 12: Jarir Atthobari - Clinical Trial](https://reader033.vdocuments.mx/reader033/viewer/2022051314/54fa9aa94a7959575b8b48a9/html5/thumbnails/12.jpg)
RANDOMISASI
� 2 treatment groups: AB for 0-4; BA for 5-9
� 3 treatment groups:ABC= 1; ACB= 2; BAC= 3BCA= 4; CAB= 5; CBA= 6
� 2 treatment group with block of 4 patientAABB= 1; ABAB= 2; ABBA= 3BBAA= 4; BABA= 5; BAAB= 6
Random permuted blocksRandom permuted blocks
![Page 13: Jarir Atthobari - Clinical Trial](https://reader033.vdocuments.mx/reader033/viewer/2022051314/54fa9aa94a7959575b8b48a9/html5/thumbnails/13.jpg)
4.BLINDING
� To prevent bias� To prevent prediction effect� Objective measures� Reducing risk of overwhelming
examination
Aims:Aims:
![Page 14: Jarir Atthobari - Clinical Trial](https://reader033.vdocuments.mx/reader033/viewer/2022051314/54fa9aa94a7959575b8b48a9/html5/thumbnails/14.jpg)
RCTs according to whether the investigators and participants know which intervention is being assessed
Open trials
Triple and quadruple-blind trials
Double blind trials
Single blind trials
![Page 15: Jarir Atthobari - Clinical Trial](https://reader033.vdocuments.mx/reader033/viewer/2022051314/54fa9aa94a7959575b8b48a9/html5/thumbnails/15.jpg)
BLINDING
Single blind Double blind Triple blind
Patient Patientdoctor/rater
PatientDoctor/raterStatistician
![Page 16: Jarir Atthobari - Clinical Trial](https://reader033.vdocuments.mx/reader033/viewer/2022051314/54fa9aa94a7959575b8b48a9/html5/thumbnails/16.jpg)
5. PENGUKURAN BASELINE & OUTCOME
� Measurable� Objective� Accurate� Consistent
![Page 17: Jarir Atthobari - Clinical Trial](https://reader033.vdocuments.mx/reader033/viewer/2022051314/54fa9aa94a7959575b8b48a9/html5/thumbnails/17.jpg)
Define potential important variables
Compare between study groups
Account for differences in study design or analysis of results
Measure baseline variables
![Page 18: Jarir Atthobari - Clinical Trial](https://reader033.vdocuments.mx/reader033/viewer/2022051314/54fa9aa94a7959575b8b48a9/html5/thumbnails/18.jpg)
RCT helicobacter pylori eradication in NSAID user
![Page 19: Jarir Atthobari - Clinical Trial](https://reader033.vdocuments.mx/reader033/viewer/2022051314/54fa9aa94a7959575b8b48a9/html5/thumbnails/19.jpg)
Outcome Measures
Easy to diagnose and observeEasy to diagnose and observe
Free of measurement or ascertainment errors
Free of measurement or ascertainment errors
Can be observed independent oftreatment assignment
Can be observed independent oftreatment assignment
Chosen before the start of data collectionChosen before the start of data collection
Clinically relevant Clinically relevant
![Page 20: Jarir Atthobari - Clinical Trial](https://reader033.vdocuments.mx/reader033/viewer/2022051314/54fa9aa94a7959575b8b48a9/html5/thumbnails/20.jpg)
Measurement bias� Measurement error� Recall bias� Observer bias
![Page 21: Jarir Atthobari - Clinical Trial](https://reader033.vdocuments.mx/reader033/viewer/2022051314/54fa9aa94a7959575b8b48a9/html5/thumbnails/21.jpg)
Sumber-sumber bias
� peneliti (misalnya interviewer bias)� subyek penelitian (recall bias)� pengukuran outcome
(measurement bias)
![Page 22: Jarir Atthobari - Clinical Trial](https://reader033.vdocuments.mx/reader033/viewer/2022051314/54fa9aa94a7959575b8b48a9/html5/thumbnails/22.jpg)
� Descriptives
� Survival time: early treatment vs. dead� tumor response: reduction of tumor size
� Duration of treatment vs. treatment response� Patients improvement
� Toxicity
e.g: e.g: cytostaticscytostatics
6. Analisa data
![Page 23: Jarir Atthobari - Clinical Trial](https://reader033.vdocuments.mx/reader033/viewer/2022051314/54fa9aa94a7959575b8b48a9/html5/thumbnails/23.jpg)
Bagaimana menyajikan data descriptive?
Bagaimana menyajikan data descriptive?
�Prosentase�Mean, SD, SEM�Proporsi�RR (relative risk)
![Page 24: Jarir Atthobari - Clinical Trial](https://reader033.vdocuments.mx/reader033/viewer/2022051314/54fa9aa94a7959575b8b48a9/html5/thumbnails/24.jpg)
Bentuk penyajian
0
20
40
60
80
100
1st Qtr 2nd Qtr 3rd Qtr
EastWestNorth
1st Qtr2nd Qtr3rd Qtr4th Qtr
0
20
40
60
80
100
1st Qtr 2nd Qtr 3rd Qtr 4th Qtr
EastWestNorth
Deskripsi0
20
40
60
80
100
120
140
160
180
1st Qtr 2nd Qtr 3rd Qtr 4th Qtr
NorthWestEast
![Page 25: Jarir Atthobari - Clinical Trial](https://reader033.vdocuments.mx/reader033/viewer/2022051314/54fa9aa94a7959575b8b48a9/html5/thumbnails/25.jpg)
Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study
Lancet1998; 352: 1016–21
![Page 26: Jarir Atthobari - Clinical Trial](https://reader033.vdocuments.mx/reader033/viewer/2022051314/54fa9aa94a7959575b8b48a9/html5/thumbnails/26.jpg)
RisikoRisiko relatifrelatif (RR = Relative Risk)(RR = Relative Risk)
PenyakitPenyakit
+ + --
+ a b+ a b
-- c dc dEksposurEksposur
aa------------a + ba + b
RR = RR = ----------------------------cc
------------c + dc + d
RR = (a/RR = (a/a+ba+b) ) –– ((c/c+dc/c+d))
![Page 27: Jarir Atthobari - Clinical Trial](https://reader033.vdocuments.mx/reader033/viewer/2022051314/54fa9aa94a7959575b8b48a9/html5/thumbnails/27.jpg)
Risiko relatif (RR = Relative Risk)
Stroke
+ -
+ 10 90 = 100
- 20 80 = 100BPLD
AR = (a/a+b) – (c/c+d)
![Page 28: Jarir Atthobari - Clinical Trial](https://reader033.vdocuments.mx/reader033/viewer/2022051314/54fa9aa94a7959575b8b48a9/html5/thumbnails/28.jpg)
RR untuk elective SC : 0.24 (95% CI: 0.11 - 0.48)RR untuk non-elective SC : 0.30 (95% CI: 0.25 - 0.35)
Antibiotika profilaksi pada SC mencegah endometritis
95% Confidence interval
![Page 29: Jarir Atthobari - Clinical Trial](https://reader033.vdocuments.mx/reader033/viewer/2022051314/54fa9aa94a7959575b8b48a9/html5/thumbnails/29.jpg)
� RR = 2,45; 95% CI (1,85:2,92)
� RR = 1,85; 95% CI (0,95-2,25)
The estimate of the treatment effect?
95% Confidence interval
![Page 30: Jarir Atthobari - Clinical Trial](https://reader033.vdocuments.mx/reader033/viewer/2022051314/54fa9aa94a7959575b8b48a9/html5/thumbnails/30.jpg)
Risiko Odds (OR = Odds Ratio)
Penyakit
+ -
+ a b
- c dEksposur
a------0 + b
RR = --------------c
------0 + d
OR = ad/bc
![Page 31: Jarir Atthobari - Clinical Trial](https://reader033.vdocuments.mx/reader033/viewer/2022051314/54fa9aa94a7959575b8b48a9/html5/thumbnails/31.jpg)
Relative Risk Reduction
RRR = (|CER – EER|/CER)
CER : Control Event Rate (tanpa terapi dimaksud/plasebo)EER : Experimental Event Rate (dengan terapi dimaksud)
![Page 32: Jarir Atthobari - Clinical Trial](https://reader033.vdocuments.mx/reader033/viewer/2022051314/54fa9aa94a7959575b8b48a9/html5/thumbnails/32.jpg)
The effect of fosinopril on cardiovascular events in population with hypertension
100 patients RCT 50 placebo and 50 fosinoprilAfter 5 years 20 in placebo group and 10 in fosinopril group had CVECER (placebo, %) ?EER (fosinopril, %) ?RRR (CER-EER/CER) ?ARR (|CER-EER|) ?NNT (1/ARR) ?
100 patients RCT 50 placebo and 50 fosinoprilAfter 5 years 20 in placebo group and 10 in fosinopril group had CVECER (placebo, %) ?EER (fosinopril, %) ?RRR (CER-EER/CER) ?ARR (|CER-EER|) ?NNT (1/ARR) ?
CER = control event rateEER = experimental event rateRRR = relative risk reductionARR = absolute risk reductionNNT = number needed to treat
Event rate= cardiovascular events
![Page 33: Jarir Atthobari - Clinical Trial](https://reader033.vdocuments.mx/reader033/viewer/2022051314/54fa9aa94a7959575b8b48a9/html5/thumbnails/33.jpg)
CER (plasebo) 40%EER (fosinopril) 20%CER (plasebo) 40%EER (fosinopril) 20%
Table 5.4 EBM-Sacket
NNT (1/ARR)NNT (1/ARR)
RRR (CER-EER/CER) RRR (CER-EER/CER)
ARR (|CER-EER|) ARR (|CER-EER|)
(40% - 20%)/40% = 50%(40% - 20%)/40% = 50%
40% - 20% = 20 %40% - 20% = 20 %
1/20% = 51/20% = 5
The effect of fosinopril on cardiovascular events in population with hypertension
![Page 34: Jarir Atthobari - Clinical Trial](https://reader033.vdocuments.mx/reader033/viewer/2022051314/54fa9aa94a7959575b8b48a9/html5/thumbnails/34.jpg)
0 1 2 3 4 5 6
Tramadol 75mg
Parasetamol 650 mg
Parasetamol 1000 mg
Aspirin 650 mg
Parasetamol 650 mg + kodein 60 mg
Morfin 10 mg IM
Ibuprofen 400 mg
Ketorolak 10 mg
Naproksen 440 mg
Diklofenak 50 mg
Number Needed to Treat (NNT)
Efikasi berbagai AINS berdasarkan nilaiNNT (Number Needed to Treat)
![Page 35: Jarir Atthobari - Clinical Trial](https://reader033.vdocuments.mx/reader033/viewer/2022051314/54fa9aa94a7959575b8b48a9/html5/thumbnails/35.jpg)
• Confounding occurs when two factors are associated with each other and effect of one is confused with or distorted by the effect of the other
• A confounder is a variable which is associated with the exposure, and independent of that exposure is a risk factor of the disease
ConfoundingConfoundingConfounding
![Page 36: Jarir Atthobari - Clinical Trial](https://reader033.vdocuments.mx/reader033/viewer/2022051314/54fa9aa94a7959575b8b48a9/html5/thumbnails/36.jpg)
To be a confounding factor, two conditions must be met:
Be associated with exposure- without being the consequence of exposure
Be associated with outcome- independently of exposure (not an intermediary)
ConfoundingConfoundingConfounding
Exposure Outcome
Third variable
![Page 37: Jarir Atthobari - Clinical Trial](https://reader033.vdocuments.mx/reader033/viewer/2022051314/54fa9aa94a7959575b8b48a9/html5/thumbnails/37.jpg)
ConfoundingConfounding
Coffee CHD
Smoking
Smoking is correlated with coffee drinking and a risk factor even for those
who do not drink coffee
![Page 38: Jarir Atthobari - Clinical Trial](https://reader033.vdocuments.mx/reader033/viewer/2022051314/54fa9aa94a7959575b8b48a9/html5/thumbnails/38.jpg)
TERIMA KASIH